The water-soluble calcitonins and the water-soluble pharmaceutically-acceptable compounds of acidic nature which are effective against Paget's disease and which contain at least two acidic groups separated by not more than two carbon atoms act synergistically in inhibiting a pathological increased calcium metabolism rate (including the solubilization of bone calcium which occurs in Paget's disease). The components in combination, when administered in respectively preferred amounts, inhibit or arrest loss of calcium by the bones of the body with less severe side effects than those caused by equivalent therapeutic doses of the calcitonin alone or by equivalent therapeutic doses of the compounds of acidic nature alone.
水溶性
降钙素和
水溶性药物可接受的酸性化合物对帕吉特病有效,并且至少包含两个酸性基团,这些基团之间的碳原子数不超过两个,它们在抑制病理性增加的
钙代谢率方面具有协同作用(包括在帕吉特病中发生的骨
钙溶解)。当分别以优选剂量给予组合物时,与单独给予相当治疗剂量的
降钙素或酸性化合物相比,组分的组合物可以抑制或阻止体内骨骼失
钙,其不良副作用较轻。